{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:57:22Z","timestamp":1790704642702,"version":"4.1.0"},"reference-count":100,"publisher":"IMR Press","issue":"9","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmazie"],"abstract":"<jats:p>Lipid metabolism, coagulation, inflammation, and vascular integrity are closely interconnected biological systems. Although statins are primarily prescribed to reduce low-density lipoprotein cholesterol (LDL-C) and prevent atherosclerotic cardiovascular disease, increasing evidence indicates that these agents exert multiple pharmacological effects beyond lipid lowering, including modulation of endothelial function, platelet activation, tissue factor expression, thrombin generation, fibrinolysis, and thrombo-inflammation. These pleiotropic properties have generated growing interest in the potential role of statins as adjunctive modulators of thrombotic risk in patients receiving anticoagulant therapy. Venous thromboembolism, which includes deep vein thrombosis and pulmonary embolism, is a major clinical setting in which anticoagulant treatment reduces recurrence and mortality but exposes patients to bleeding complications. Observational studies and registry-based analyses suggest that statin use may be associated with improved outcomes among anticoagulated patients with venous thromboembolism, particularly for all-cause mortality and early survival after pulmonary embolism. At the same time, emerging evidence suggests that very low LDL-C concentrations may be associated with increased bleeding risk during anticoagulation, raising important questions regarding the relationship between lipid availability, vascular stability, platelet function, and hemostatic balance. This review summarizes current pharmacological and clinical evidence linking lipid metabolism, statin therapy, anticoagulation, thrombosis, and bleeding. Particular attention is devoted to the mechanisms through which statins influence hemostatic pathways, the clinical evidence derived from venous thromboembolism cohorts, and the potential implications of LDL-C levels for personalized bleeding risk assessment. Future strategies that integrate lipid profiles, thrombotic and bleeding risk, and pharmacological modulation of coagulation may contribute to more individualized antithrombotic management.<\/jats:p>","DOI":"10.31083\/pharmazie54718","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:05:53Z","timestamp":1790701553000},"source":"Crossref","is-referenced-by-count":0,"title":["Lipid Metabolism, Statins and Bleeding Risk During Anticoagulant Therapy: Emerging Pharmacological Insights"],"prefix":"10.31083","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0613-1074","authenticated-orcid":true,"given":"Carmine","family":"Siniscalchi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Parma University Hospital, 43125 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Basaglia","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Parma University Hospital, 43125 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Perrella","sequence":"additional","affiliation":[{"name":"Department of Emerging Infectious Disease and High Contagiousness, Ospedale dei Colli, PO D. Cotugno, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Futura","family":"Bernardi","sequence":"additional","affiliation":[{"name":"Coordination of the Regional Health System, General Directorate for Health Protection, Department of Experimental Medicine, University of Campania Luigi Vanvitelli, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierpaolo","family":"Di Micco","sequence":"additional","affiliation":[{"name":"Internal Medicine Ward, Santa Maria delle Grazie Hospital, 80122 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149: 315\u2013352.","DOI":"10.1016\/j.chest.2015.11.026"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). European Heart Journal. 2020; 41: 543\u2013603.","DOI":"10.1093\/eurheartj\/ehz405"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868\u2013874.","DOI":"10.1038\/nature01323"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Mackman N. New insights into the mechanisms of venous thrombosis. The Journal of Clinical Investigation. 2012; 122: 2331\u20132336.","DOI":"10.1172\/JCI60229"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004; 109: III39\u2013III43.","DOI":"10.1161\/01.CIR.0000131517.20177.5a"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Liao JK, Laufs U. Pleiotropic effects of statins. Annual Review of Pharmacology and Toxicology. 2005; 45: 89\u2013118.","DOI":"10.1146\/annurev.pharmtox.45.120403.095748"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005; 25: 287\u2013294.","DOI":"10.1161\/01.ATV.0000151647.14923.ec"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Undas A, Celinska-L\u00f6wenhoff M, Brummel-Ziedins KE, Brozek J, Szczeklik A, Mann KG. Simvastatin given for 3 days can inhibit thrombin generation and activation of factor V and enhance factor Va inactivation in hypercholesterolemic patients. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005; 25: 1524\u20131525.","DOI":"10.1161\/01.ATV.0000168913.25278.38"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Glynn RJ, Danielson E, Fonseca FAH, Genest J, Gotto AM Jr, Kastelein JJP, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. The New England Journal of Medicine. 2009; 360: 1851\u20131861.","DOI":"10.1056\/NEJMoa0900241"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Siniscalchi C, Quintavalla R, Rocci A, Riera-Mestre A, Trujillo-Santos J, Suri\u00f1ach JM, et al. Statin and all-cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE registry. European Journal of Internal Medicine. 2019; 68: 30\u201335.","DOI":"10.1016\/j.ejim.2019.07.028"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Siniscalchi C, Muriel A, Suri\u00f1ach Caralt JM, Bikdeli B, Jim\u00e9nez D, Lobo JL, et al. Statin use and 30-day mortality in patients with acute symptomatic pulmonary embolism. Journal of Thrombosis and Haemostasis : JTH. 2022; 20: 1839\u20131851.","DOI":"10.1111\/jth.15753"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Siniscalchi C, Bikdeli B, Jim\u00e9nez D, Suri\u00f1ach JM, Demelo-Rodr\u00edguez P, Moustafa F, et al. Statin use and mortality in patients with deep vein thrombosis. Data from the RIETE Registry. Thrombosis Research. 2024; 236: 88\u201396.","DOI":"10.1016\/j.thromres.2024.02.024"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. The New England Journal of Medicine. 2006; 355: 549\u2013559.","DOI":"10.1056\/NEJMoa061894"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke. 2012; 43: 2149\u20132156.","DOI":"10.1161\/STROKEAHA.112.655894"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Siniscalchi C, Meschi T, Di Micco P, Imbalzano E, Hern\u00e1ndez-Blasco L, Mah\u00e9 I, et al. Low-Density Lipoprotein Cholesterol Levels and Bleeding Risk in Venous Thromboembolism. JAMA Network Open. 2025; 8: e259467.","DOI":"10.1001\/jamanetworkopen.2025.9467"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Borissoff JI, Spronk HMH, ten Cate H. The hemostatic system as a modulator of atherosclerosis. The New England Journal of Medicine. 2011; 364: 1746\u20131760.","DOI":"10.1056\/NEJMra1011670"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Monroe DM, Hoffman M. What does it take to make the perfect clot? Arteriosclerosis, Thrombosis, and Vascular Biology. 2006; 26: 41\u201348.","DOI":"10.1161\/01.ATV.0000193624.28251.83"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Penn MS, Patel CV, Cui MZ, DiCorleto PE, Chisolm GM. LDL increases inactive tissue factor on vascular smooth muscle cell surfaces: hydrogen peroxide activates latent cell surface tissue factor. Circulation. 1999; 99: 1753\u20131759.","DOI":"10.1161\/01.cir.99.13.1753"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Steinberg D. The LDL modification hypothesis of atherogenesis: an update. Journal of Lipid Research. 2009; 50: S376\u2013S381.","DOI":"10.1194\/jlr.R800087-JLR200"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Lowe GDO. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. Journal of Thrombosis and Haemostasis : JTH. 2005; 3: 1618\u20131627.","DOI":"10.1111\/j.1538-7836.2005.01416.x"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Undas A, Top\u00f3r-Madry R, Tracz W. Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4 mmol\/l. Polskie Archiwum Medycyny Wewnetrznej. 2009; 119: 354\u2013359.","DOI":"10.20452\/pamw.707"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation. 2008; 117: 93\u2013102.","DOI":"10.1161\/CIRCULATIONAHA.107.709204"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Undas A, Ari\u00ebns RAS. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arteriosclerosis, Thrombosis, and Vascular Biology. 2011; 31: e88\u2013e99.","DOI":"10.1161\/ATVBAHA.111.230631"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Shattil SJ, Newman PJ. Integrins: dynamic scaffolds for adhesion and signaling in platelets. Blood. 2004; 104: 1606\u20131615.","DOI":"10.1182\/blood-2004-04-1257"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nature Medicine. 2007; 13: 1086\u20131095.","DOI":"10.1038\/nm1626"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Massberg S, Brand K, Gr\u00fcner S, Page S, M\u00fcller E, M\u00fcller I, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. The Journal of Experimental Medicine. 2002; 196: 887\u2013896.","DOI":"10.1084\/jem.20012044"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Violi F, Pignatelli P. Platelet oxidative stress and thrombosis. Thrombosis Research. 2012; 129: 378\u2013381.","DOI":"10.1016\/j.thromres.2011.12.002"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Wang X, Dong Y, Qi X, Huang C, Hou L. Cholesterol levels and risk of hemorrhagic stroke: a systematic review and meta-analysis. Stroke. 2013; 44: 1833\u20131839.","DOI":"10.1161\/STROKEAHA.113.001326"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Gimbrone MA Jr, Garc\u00eda-Carde\u00f1a G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circulation Research. 2016; 118: 620\u2013636.","DOI":"10.1161\/CIRCRESAHA.115.306301"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiological Reviews. 2004; 84: 1381\u20131478.","DOI":"10.1152\/physrev.00047.2003"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"St\u0119pie\u0144 K, Natorska J, Z\u0105bczyk M, Zalewski J, Jawie\u0144 J, Undas A. High-dose atorvastatin and rosuvastatin reduce the levels of neutrophil extracellular trap-related proteins in coronary artery disease: association with prothrombotic state. Polish Archives of Internal Medicine. 2024; 134: 16852.","DOI":"10.20452\/pamw.16852"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"D\u00f6ring Y, Libby P, Soehnlein O. Neutrophil Extracellular Traps Participate in Cardiovascular Diseases: Recent Experimental and Clinical Insights. Circulation Research. 2020; 126: 1228\u20131241.","DOI":"10.1161\/CIRCRESAHA.120.315931"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Cao J, Chen Y. The impact of vascular endothelial glycocalyx on the pathogenesis and treatment of disseminated intravascular coagulation. Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis. 2023; 34: 465\u2013470.","DOI":"10.1097\/MBC.0000000000001257"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Flora GD, Nayak MK, Ghatge M, Chauhan AK. Metabolic targeting of platelets to combat thrombosis: dawn of a new paradigm? Cardiovascular Research. 2023; 119: 2497\u20132507.","DOI":"10.1093\/cvr\/cvad149"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity. Nature Reviews. Immunology. 2013; 13: 34\u201345.","DOI":"10.1038\/nri3345"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999; 100: 230\u2013235.","DOI":"10.1161\/01.cir.100.3.230"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM Jr, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine. 2008; 359: 2195\u20132207.","DOI":"10.1056\/NEJMoa0807646"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation. 2001; 103: 1718\u20131720.","DOI":"10.1161\/01.cir.103.13.1718"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke. 2004; 35: 2708\u20132711.","DOI":"10.1161\/01.STR.0000143319.73503.38"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Oesterle A, Laufs U, Liao JK. Pleiotropic Effects of Statins on the Cardiovascular System. Circulation Research. 2017; 120: 229\u2013243.","DOI":"10.1161\/CIRCRESAHA.116.308537"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015; 161: 161\u2013172.","DOI":"10.1016\/j.cell.2015.01.036"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundamental & Clinical Pharmacology. 2005; 19: 117\u2013125.","DOI":"10.1111\/j.1472-8206.2004.00299.x"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nature Reviews. Drug Discovery. 2005; 4: 977\u2013987.","DOI":"10.1038\/nrd1901"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation\/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001; 286: 64\u201370.","DOI":"10.1001\/jama.286.1.64"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Branchford BR, Carpenter SL. The Role of Inflammation in Venous Thromboembolism. Frontiers in Pediatrics. 2018; 6: 142.","DOI":"10.3389\/fped.2018.00142"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Yau JW, Teoh H, Verma S. Endothelial cell control of thrombosis. BMC Cardiovascular Disorders. 2015; 15: 130.","DOI":"10.1186\/s12872-015-0124-z"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998; 97: 1129\u20131135.","DOI":"10.1161\/01.cir.97.12.1129"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Romano M, Mezzetti A, Marulli C, Ciabattoni G, Febo F, Di Ienno S, et al. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide. Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research. 2000; 48: 183\u2013189.","DOI":"10.1177\/108155890004800305"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Prasad A, Zhu J, Halcox JPJ, Waclawiw MA, Epstein SE, Quyyumi AA. Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation. 2002; 106: 184\u2013190.","DOI":"10.1161\/01.cir.0000021125.83697.21"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Colli S, Eligini S, Lalli M, Camera M, Paoletti R, Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 1997; 17: 265\u2013272.","DOI":"10.1161\/01.atv.17.2.265"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Undas A, Brummel-Ziedins KE, Mann KG. Anticoagulant effects of statins and their clinical implications. Thrombosis and Haemostasis. 2014; 111: 392\u2013400.","DOI":"10.1160\/TH13-08-0720"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Adams NB, Lutsey PL, Folsom AR, Herrington DH, Sibley CT, Zakai NA, et al. Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis. Journal of Thrombosis and Haemostasis : JTH. 2013; 11: 1078\u20131084.","DOI":"10.1111\/jth.12223"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Siniscalchi C, Basaglia M, Riva M, Meschi M, Meschi T, Castaldo G, et al. Statins Effects on Blood Clotting: A Review. Cells. 2023; 12: 2719.","DOI":"10.3390\/cells12232719"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Undas A, Celinska-L\u00f6wenhoff M, L\u00f6wenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. Journal of Thrombosis and Haemostasis : JTH. 2006; 4: 1029\u20131036.","DOI":"10.1111\/j.1538-7836.2006.01882.x"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Sahebkar A, Catena C, Ray KK, Vallejo-Vaz AJ, Reiner \u017d, Sechi LA, et al. Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. A systematic review and meta-analysis of randomised controlled trials. Thrombosis and Haemostasis. 2016; 116: 162\u2013171.","DOI":"10.1160\/TH15-10-0770"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Sanguigni V, Pignatelli P, Lenti L, Ferro D, Bellia A, Carnevale R, et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation. 2005; 111: 412\u2013419.","DOI":"10.1161\/01.CIR.0000153810.81187.7D"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Puccetti L, Pasqui AL, Pastorelli M, Bova G, Di Renzo M, Leo A, et al. Platelet hyperactivity after statin treatment discontinuation. Thrombosis and Haemostasis. 2003; 90: 476\u2013482.","DOI":"10.1160\/TH03-02-0111"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Tousoulis D, Psarros C, Demosthenous M, Patel R, Antoniades C, Stefanadis C. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. Journal of the American College of Cardiology. 2014; 63: 2491\u20132502.","DOI":"10.1016\/j.jacc.2014.01.054"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Ray JG, Mamdani M, Tsuyuki RT, Anderson DR, Yeo EL, Laupacis A. Use of statins and the subsequent development of deep vein thrombosis. Archives of Internal Medicine. 2001; 161: 1405\u20131410.","DOI":"10.1001\/archinte.161.11.1405"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Lacut K, Le Gal G, Abalain JH, Mottier D, Oger E. Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia? Thrombosis Research. 2008; 122: 314\u2013319.","DOI":"10.1016\/j.thromres.2007.10.014"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Rahimi K, Bhala N, Kamphuisen P, Emberson J, Biere-Rafi S, Krane V, et al. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. PLoS Medicine. 2012; 9: e1001310.","DOI":"10.1371\/journal.pmed.1001310"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Squizzato A, Galli M, Romualdi E, Dentali F, Kamphuisen PW, Guasti L, et al. Statins, fibrates, and venous thromboembolism: a meta-analysis. European Heart Journal. 2010; 31: 1248\u20131256.","DOI":"10.1093\/eurheartj\/ehp556"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Bikdeli B, Jimenez D, Hawkins M, Ort\u00edz S, Prandoni P, Brenner B, et al. Rationale, Design and Methodology of the Computerized Registry of Patients with Venous Thromboembolism (RIETE). Thrombosis and Haemostasis. 2018; 118: 214\u2013224.","DOI":"10.1160\/TH17-07-0511"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Li R, Yuan M, Yu S, Fu W, Yu W, Ling S, et al. Effect of statins on the risk of recurrent venous thromboembolism: A systematic review and meta-analysis. Pharmacological Research. 2021; 165: 105413.","DOI":"10.1016\/j.phrs.2020.105413"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Becattini C, Agnelli G. Acute pulmonary embolism: risk stratification in the emergency department. Internal and Emergency Medicine. 2007; 2: 119\u2013129.","DOI":"10.1007\/s11739-007-0033-y"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Bagot CN, Arya R. Virchow and his triad: a question of attribution. British Journal of Haematology. 2008; 143: 180\u2013190.","DOI":"10.1111\/j.1365-2141.2008.07323.x"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Dubois-Silva \u00c1, Barbagelata-L\u00f3pez C, Pi\u00f1eiro-Parga P, Francisco I, Falg\u00e1 C, Tirado R, et al. Prognostic Significance of Concomitant Superficial Vein Thrombosis in Patients with Deep Vein Thrombosis of the Lower Limbs. Thrombosis and Haemostasis. 2021; 121: 1650\u20131659.","DOI":"10.1055\/a-1414-5055"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Farmakis IT, Christodoulou KC, Hobohm L, Konstantinides SV, Valerio L. Lipid lowering for prevention of venous thromboembolism: a network meta-analysis. European Heart Journal. 2024; 45: 3219\u20133227.","DOI":"10.1093\/eurheartj\/ehae361"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Hanigan S, Das J, Pogue K, Barnes GD, Dorsch MP. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. Journal of Thrombosis and Thrombolysis. 2020; 49: 636\u2013643.","DOI":"10.1007\/s11239-020-02037-3"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021; 23: 1612\u20131676.","DOI":"10.1093\/europace\/euab065"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Khan F, Tritschler T, Kimpton M, Wells PS, Kearon C, Weitz JI, et al. Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism : A Systematic Review and Meta-analysis. Annals of Internal Medicine. 2021; 174: 1420\u20131429.","DOI":"10.7326\/m21-1094"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Xie L, Wu W, Chen J, Tu J, Zhou J, Qi X, et al. Cholesterol Levels and Hemorrhagic Stroke Risk in East Asian Versus Non-East Asian Populations: A Systematic Review and Meta-Analysis. The Neurologist. 2017; 22: 107\u2013115.","DOI":"10.1097\/NRL.0000000000000126"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Wu Z, Huang Z, Lichtenstein AH, Liu Y, Chen S, Jin Y, et al. The risk of ischemic stroke and hemorrhagic stroke in Chinese adults with low-density lipoprotein cholesterol concentrations < 70 mg\/dL. BMC Medicine. 2021; 19: 142.","DOI":"10.1186\/s12916-021-02014-4"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Hellfritzsch M, Henriksen JN, Holt MI, Grove EL. Drug-Drug Interactions in the Treatment of Cancer-Associated Venous Thromboembolism with Direct Oral Anticoagulants. Seminars in Thrombosis and Hemostasis. 2024; 50: 489\u2013498.","DOI":"10.1055\/s-0043-1762596"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Riess H, Prandoni P, Harder S, Kreher S, Bauersachs R. Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: Potential for drug-drug interactions. Critical Reviews in Oncology\/hematology. 2018; 132: 169\u2013179.","DOI":"10.1016\/j.critrevonc.2018.09.015"},{"key":"ref76","doi-asserted-by":"publisher","unstructured":"Derebail VK, Rheault MN, Kerlin BA. Role of direct oral anticoagulants in patients with kidney disease. Kidney International. 2020; 97: 664\u2013675.","DOI":"10.1016\/j.kint.2019.11.027"},{"key":"ref77","doi-asserted-by":"publisher","unstructured":"Sarnak MJ, Bloom R, Muntner P, Rahman M, Saland JM, Wilson PWF, et al. KDOQI US commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 2015; 65: 354\u2013366.","DOI":"10.1053\/j.ajkd.2014.10.005"},{"key":"ref78","doi-asserted-by":"publisher","unstructured":"Giral P, Moulin P, Rosenbaum D. Efficacy and safety of more intensive lowering of LDL cholesterol. Lancet (London, England). 2011; 377: 715; author reply 715\u20136.","DOI":"10.1016\/S0140-6736(11)60262-6"},{"key":"ref79","doi-asserted-by":"publisher","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. The New England Journal of Medicine. 2017; 376: 1713\u20131722.","DOI":"10.1056\/NEJMoa1615664"},{"key":"ref80","doi-asserted-by":"publisher","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. The New England Journal of Medicine. 2018; 379: 2097\u20132107.","DOI":"10.1056\/NEJMoa1801174"},{"key":"ref81","doi-asserted-by":"publisher","unstructured":"Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet (London, England). 2016; 388: 2532\u20132561.","DOI":"10.1016\/S0140-6736(16)31357-5"},{"key":"ref82","doi-asserted-by":"publisher","unstructured":"Ikonen E. Cellular cholesterol trafficking and compartmentalization. Nature Reviews. Molecular Cell Biology. 2008; 9: 125\u2013138.","DOI":"10.1038\/nrm2336"},{"key":"ref83","doi-asserted-by":"publisher","unstructured":"Nenna A, Nappi F, Lusini M, Satriano UM, Schilir\u00f2 D, Spadaccio C, et al. Effect of Statins on Platelet Activation and Function: From Molecular Pathways to Clinical Effects. BioMed Research International. 2021; 2021: 6661847.","DOI":"10.1155\/2021\/6661847"},{"key":"ref84","doi-asserted-by":"publisher","unstructured":"Lowe GDO, Rumley A, Mackie IJ. Plasma fibrinogen. Annals of Clinical Biochemistry. 2004; 41: 430\u2013440.","DOI":"10.1258\/0004563042466884"},{"key":"ref85","doi-asserted-by":"publisher","unstructured":"Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. The New England Journal of Medicine. 1989; 320: 904\u2013910.","DOI":"10.1056\/NEJM198904063201405"},{"key":"ref86","doi-asserted-by":"publisher","unstructured":"Yano K, Reed DM, MacLean CJ. Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke. 1989; 20: 1460\u20131465.","DOI":"10.1161\/01.str.20.11.1460"},{"key":"ref87","doi-asserted-by":"publisher","unstructured":"Ma C, Gurol ME, Huang Z, Lichtenstein AH, Wang X, Wang Y, et al. Low-density lipoprotein cholesterol and risk of intracerebral hemorrhage: A prospective study. Neurology. 2019; 93: e445\u2013e457.","DOI":"10.1212\/WNL.0000000000007853"},{"key":"ref88","doi-asserted-by":"publisher","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis : JTH. 2005; 3: 692\u2013694.","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"ref89","doi-asserted-by":"publisher","unstructured":"Schupf N, Costa R, Luchsinger J, Tang MX, Lee JH, Mayeux R. Relationship between plasma lipids and all-cause mortality in nondemented elderly. Journal of the American Geriatrics Society. 2005; 53: 219\u201326.","DOI":"10.1111\/j.1532-5415.2005.53106.x"},{"key":"ref90","doi-asserted-by":"publisher","unstructured":"B\u00e9trisey S, Haller ML, Efthimiou O, Speierer A, Del Giovane C, Moutzouri E, et al. Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of the American Heart Association. 2024; 13: e030714.","DOI":"10.1161\/JAHA.123.030714"},{"key":"ref91","doi-asserted-by":"publisher","unstructured":"Goldstein LB, Toth PP, Dearborn-Tomazos JL, Giugliano RP, Hirsh BJ, Pe\u00f1a JM, et al. Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. 2023; 43: e404\u2013e442.","DOI":"10.1161\/ATV.0000000000000164"},{"key":"ref92","doi-asserted-by":"publisher","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. The New England Journal of Medicine. 2017; 377: 1319\u20131330.","DOI":"10.1056\/NEJMoa1709118"},{"key":"ref93","doi-asserted-by":"publisher","unstructured":"Klok FA, Huisman MV. How I assess and manage the risk of bleeding in patients treated for venous thromboembolism. Blood. 2020; 135: 724\u2013734.","DOI":"10.1182\/blood.2019001605"},{"key":"ref94","doi-asserted-by":"publisher","unstructured":"Boon GJAM, Barco S, Bertoletti L, Ghanima W, Huisman MV, Kahn SR, et al. Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale. Thrombosis Research. 2020; 190: 45\u201351.","DOI":"10.1016\/j.thromres.2020.03.020"},{"key":"ref95","doi-asserted-by":"publisher","unstructured":"van Es N, Coppens M, Schulman S, Middeldorp S, B\u00fcller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014; 124: 1968\u20131975.","DOI":"10.1182\/blood-2014-04-571232"},{"key":"ref96","doi-asserted-by":"publisher","unstructured":"Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, et al. D-dimer testing to determine the duration of anticoagulation therapy. The New England Journal of Medicine. 2006; 355: 1780\u20131789.","DOI":"10.1056\/NEJMoa054444"},{"key":"ref97","doi-asserted-by":"publisher","unstructured":"Siniscalchi C, Di Micco P. Age-Adjusted D-Dimer Cutoffs to Exclude DVT. JAMA. 2026; 335: 1817\u20131818.","DOI":"10.1001\/jama.2026.2842"},{"key":"ref98","doi-asserted-by":"publisher","unstructured":"Goldstein BA, Navar AM, Carter RE. Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges. European Heart Journal. 2017; 38: 1805\u20131814.","DOI":"10.1093\/eurheartj\/ehw302"},{"key":"ref99","doi-asserted-by":"publisher","unstructured":"Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacological Reviews. 2013; 65: 987\u20131009.","DOI":"10.1124\/pr.112.007252"},{"key":"ref100","doi-asserted-by":"publisher","unstructured":"Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, et al. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA. 2019; 321: 364\u2013373.","DOI":"10.1001\/jama.2018.20045"}],"container-title":["Pharmazie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/Pharmazie\/81\/9\/10.31083\/Pharmazie54718","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:06:02Z","timestamp":1790701562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/Pharmazie\/81\/9\/10.31083\/Pharmazie54718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":100,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"alternative-id":["S3053-691X(26)04690-0"],"URL":"https:\/\/doi.org\/10.31083\/pharmazie54718","relation":{},"ISSN":["0031-7144","3053-691X"],"issn-type":[{"value":"0031-7144","type":"print"},{"value":"3053-691X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"54718"}}